Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on April 2, 2019. The report discloses a material event regarding the presentation of early clinical data at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development update and does not contain financial statements.
Material Changes and Clinical Update
- Event: Presentation of early data from an ongoing Phase 2 study.
- Drug Candidate: Onvansertib.
- Combination Therapy: Zytiga (abiraterone acetate)/prednisone.
- Indication: Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- Comparison: No prior comparable period financial or clinical data is provided within this specific filing text.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the inherent uncertainties of clinical trials. The primary purpose is to disclose the public presentation of clinical data as an "Other Event" under Item 8.01.
Investor Verification Checklist
- Verify the full content of the press release attached as Exhibit 99.1 for specific clinical data points (e.g., response rates, safety profile).
- Confirm the current status of the Phase 2 study for Onvansertib in mCRPC.
- Review the company's most recent 10-Q or 10-K for actual financial metrics, as this 8-K contains none.
- Note the registrant name is Trovagene, Inc., distinct from Cardiff Oncology, Inc.